Repligen (RGEN)
(Delayed Data from NSDQ)
$145.93 USD
-1.25 (-0.85%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $146.02 +0.09 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.93 USD
-1.25 (-0.85%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $146.02 +0.09 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.
Inovio Up on Enrollment Closure in Cervical Dysplasia Study
by Zacks Equity Research
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
Pacira Gets EMA Acceptance for Pain Management Drug Exparel
by Zacks Equity Research
The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin
by Zacks Equity Research
The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.
Repligen Corporation (RGEN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Repligen Corporation (RGEN).
Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
by Zacks Equity Research
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
by Zacks Equity Research
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
Wall Street Foresees a Fed Rate Cut: Winners & Losers
by Tirthankar Chakraborty
Some analysts have started to price in "insurance cuts," which means they are expecting the Fed to cut rates right before a downturn in order to save the economy.
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
Athenex Rallies on Positive Early Data on Psoriasis Candidate
by Zacks Equity Research
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.
Looking for a Growth Stock? 3 Reasons Why Repligen (RGEN) is a Solid Choice
by Zacks Equity Research
Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
by Zacks Equity Research
BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.
5 Biotech Stocks to Buy Right Now
by Zachary Stutler
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.
The Zacks Analyst Blog Highlights: HEICO, Group 1 Automotive, Rent-A-Center, Repligen and Strategic Education
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HEICO, Group 1 Automotive, Rent-A-Center, Repligen and Strategic Education
U.S. Heading for Largest Economic Expansion: 5 Top Picks
by Nalak Das
According to the National Bureau of Economic Research, the ongoing expansion started back in June 2009.
Mesoblast Starts Rolling BLA Submission for Remestemcel-L
by Zacks Equity Research
Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.
Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems
by Zacks Equity Research
Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems
3 Reasons Why Growth Investors Shouldn't Overlook Repligen (RGEN)
by Zacks Equity Research
Repligen (RGEN) could produce exceptional returns because of its solid growth attributes.
5 Stocks With Recent Price Strength Despite Trade Concerns
by Nalak Das
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Mallinckrodt Ends Enrollment in Phase III for Terlipressin
by Zacks Equity Research
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 7.69% and 0.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?